In last week’s post I focused on how socio-techno advancements, a balanced patient outreach plan, and optimal outreach strategies work to enhance patient recruitment and engagement. While those three trends are painting a picture for how to optimize the clinical trial practices of the future, there are two more top trends that will help to round out any campaign.
We recently posted about the consumerization of health care that is truly driving change. Today I’d like to look at a few trends to keep an eye on that will prepare us for clinical trial success in the coming years.
Topics: clinical trials
Partnering with advocacy groups is a vital component to any clinical trial outreach effort. The approach to working with advocacy groups has changed in recent years. It is not just about the one connection you may have with one organization. These days it’s about working with the condition community as a whole for one common goal. Advocacy groups often have direct connections to people affected by a condition and can be highly beneficial to enrollment throughout the patient recruitment process.
At the 2015 DIA Annual Meeting this past June there was a lot of talk about how technology is impacting the way we interact with patients, sites, and other key players in the clinical study landscape. When I sat down with three other industry experts to discuss bringing clinical trial practices into the 21st century, I shifted the talk to focus on the forces that drive the way we communicate with patients and with each other within our industry. Furthermore, how can we look at today’s trends to better predict the future of patient recruitment and engagement?
Topics: Patient Recruitment
Part I of our blog series on adaptive patient recruitment focused on the importance of early support. Part II looked at how to best analyze investigator resources to optimize patient recruitment efforts, including cultivating integrated relationships. Today we wrap up our rare disease series on recruitment with two final tactics that can yield strong results.
Topics: Rare Disease
Planning. Strategy. Execution. Most would agree they form the foundation for patient recruitment. In today’s pressure filled clinical research environment, optimized enrollment is an imperative. However, in the rush to enroll on-time or ahead of schedule, certain strategies and executional elements can often be compromised. Global studies are particularly at risk due to their operational complexities.
Last week on the blog we highlighted BBK’s RSG® Arrive service, which underscores our commitment to patient centricity by easing study visit travel complexities and in turn, expanding clinical research participation. We know that travel can be a hassle, but what if getting a patient to a site could mean the difference between receiving a potentially life-saving treatment or not? What makes a patient travel program such an integral part of the clinical trial landscape?
Topics: Patient Centricity
At the 2015 DIA Annual Meeting in June, we sat down PharmaVOICE Editor Taren Grom and Claire Meunier, Vice President of Research Engagement at the Michael J. Fox Foundation for a conversation about patient centricity and the role technology is playing and will continue to play as we move forward.
We are pleased to announce that BBK’s Head of Global Media Strategy Sarah Mandracchia has been named to this year’s PharmaVOICE 100 – the magazine’s annual list of individuals recognized for their positive contributions to the life sciences industry.